Picture courtesy The Indian Express
Pune: Serum Institute of India (SII) has sought emergency use authorisation (EUA) for its COVID-19 vaccine Covovax for the 12-17 age group.
Prakash Kumar Singh, Director, Government and Regulatory Affairs at SII, stated in the application that data from two studies on 2,707 children aged 12 to 17 years show that Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group, The Indian Express reported quoting official sources.
The Drugs Controller General Of India (DCGI) has already approved Covovax for emergency use among adults.
Covovax is produced in India by Pune-based Serum Institute through technology transfer from American biotechnology company Novavax.
Earlier today, DCGI granted emergency use approval to Biological E’s indigenous vaccine Corbevax for children aged 12 to 17 years.
Currently, only those in the 15-17 year age group are being inoculated in India.
Ranchi/Bhubaneswar: Kalpana Soren, wife of Jharkhand Mukti Morcha (JMM) leader Hemant Soren Hemant Soren, was…
Mumbai: Once dubbed as the Chanakya of Maharashtra politics, Sharad Pawar has faced a significant…
Bhubaneswar: All the government departments in Odisha have been directed to ensure payment of full…
Bhubaneswar: The Odisha government has begun preparations for the five-day visit of President Droupadi Murmu…
Bhubaneswar: The state government is all set to amend the Odisha Universities (Amendment) Act, 2020…
Bhubaneswar: A low-pressure area formed over east Equatorial Indian Ocean and adjoining southeast Bay of…
Uttar Pradesh: The counting of votes for nine seats in the Uttar Pradesh Assembly bypolls…
Bhubaneswar: The Enforcement Directorate (ED) on Saturday raided the offices and residence of real estate…